11/22
10:19 am
insm
Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at JPMorgan Chase & Co. from $74.00 to $83.00. They now have an "overweight" rating on the stock.
Low
Report
Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at JPMorgan Chase & Co. from $74.00 to $83.00. They now have an "overweight" rating on the stock.
11/7
08:00 am
insm
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Low
Report
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11/6
08:00 am
insm
Insmed To Present at November 2024 Investor Conferences
Medium
Report
Insmed To Present at November 2024 Investor Conferences
11/1
11:27 am
insm
Insmed Incorporated (NASDAQ: INSM) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $105.00 price target on the stock, up previously from $100.00.
Low
Report
Insmed Incorporated (NASDAQ: INSM) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $105.00 price target on the stock, up previously from $100.00.
11/1
10:55 am
insm
Insmed's Q3 Loss Wider Than Expected, Sales In Line With Estimates [Yahoo! Finance]
Low
Report
Insmed's Q3 Loss Wider Than Expected, Sales In Line With Estimates [Yahoo! Finance]
11/1
09:29 am
insm
Do You Believe in the Growth Potential of Insmed (INSM)? [Yahoo! Finance]
Low
Report
Do You Believe in the Growth Potential of Insmed (INSM)? [Yahoo! Finance]
11/1
08:15 am
insm
Insmed Incorporated (NASDAQ: INSM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Low
Report
Insmed Incorporated (NASDAQ: INSM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
11/1
06:42 am
insm
Insmed Third Quarter 2024 Earnings: EPS Misses Expectations [Yahoo! Finance]
Low
Report
Insmed Third Quarter 2024 Earnings: EPS Misses Expectations [Yahoo! Finance]
10/31
07:00 am
insm
Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update
Low
Report
Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update
10/29
05:58 pm
insm
How to play biotech stocks: Insmed and Wave Life Sciences [Yahoo! Finance Canada]
Low
Report
How to play biotech stocks: Insmed and Wave Life Sciences [Yahoo! Finance Canada]
10/29
05:55 pm
insm
How to play biotech stocks: Insmed and Wave Life Sciences [Yahoo! Finance]
Low
Report
How to play biotech stocks: Insmed and Wave Life Sciences [Yahoo! Finance]
10/24
04:05 pm
insm
Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List
Low
Report
Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List
10/23
08:00 am
insm
Insmed Unites Across Communities Around the World During Third Annual Global Day of Good
Low
Report
Insmed Unites Across Communities Around the World During Third Annual Global Day of Good
10/17
08:00 am
insm
Insmed to Host Third-Quarter 2024 Financial Results Conference Call on Thursday, October 31, 2024
Medium
Report
Insmed to Host Third-Quarter 2024 Financial Results Conference Call on Thursday, October 31, 2024
10/11
09:41 am
insm
Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Truist Financial Co. from $85.00 to $100.00. They now have a "buy" rating on the stock.
Medium
Report
Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Truist Financial Co. from $85.00 to $100.00. They now have a "buy" rating on the stock.
10/9
02:40 pm
insm
Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Bank of America Co. from $84.00 to $86.00. They now have a "buy" rating on the stock.
Low
Report
Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Bank of America Co. from $84.00 to $86.00. They now have a "buy" rating on the stock.
10/9
06:50 am
insm
Inovio (INO) Surges 6.8%: Is This an Indication of Further Gains? [Yahoo! Finance]
Low
Report
Inovio (INO) Surges 6.8%: Is This an Indication of Further Gains? [Yahoo! Finance]
10/8
04:05 pm
insm
New Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results
Low
Report
New Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results
10/4
08:00 am
insm
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Low
Report
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
10/3
12:23 pm
insm
Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at JPMorgan Chase & Co. from $72.00 to $74.00. They now have an "overweight" rating on the stock.
Low
Report
Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at JPMorgan Chase & Co. from $72.00 to $74.00. They now have an "overweight" rating on the stock.
9/26
12:38 am
insm
Is Insmed Inc. (INSM) the Best Performing Stock in 2024? [Yahoo! Finance]
Low
Report
Is Insmed Inc. (INSM) the Best Performing Stock in 2024? [Yahoo! Finance]
9/24
08:19 am
insm
Should Vanguard Russell 2000 ETF (VTWO) Be on Your Investing Radar? [Yahoo! Finance]
Low
Report
Should Vanguard Russell 2000 ETF (VTWO) Be on Your Investing Radar? [Yahoo! Finance]
9/24
08:19 am
insm
Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar? [Yahoo! Finance]
Low
Report
Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar? [Yahoo! Finance]
9/11
06:09 am
insm
Insmed Incorporated (INSM) Surged Following Positive Data For its Drug [Yahoo! Finance]
Low
Report
Insmed Incorporated (INSM) Surged Following Positive Data For its Drug [Yahoo! Finance]
9/9
02:14 pm
insm
Insmed Incorporated (NASDAQ: INSM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Insmed Incorporated (NASDAQ: INSM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.